Search - tctmd.com

Displaying 261 - 280 of 777

Sort: Relevancy | Date

Presentation EuroPCR 2022

Blood pressure and MACE reductions after renal denervation: 3-year GSR results

Presenter: Felix Mahfoud

May 20, 2022

Presentation EuroPCR 2022

Patient-Level Pooled Analysis of Ultrasound RDN in RADIANCE-HTN SOLO and TRIO

Presenter: Ajay J. Kirtane, Michel Azizi

May 17, 2022

Presentation ARCH 2022

Current Status and Future of Renal Denervation for Hypertension

Presenter: Tim A. Fischell

April 23, 2022

Presentation ARCH 2022

Anesthesia Update: Dealing with High-Risk Pulmonary Hypertension Patients

Presenter: Jonathan Zoller

April 23, 2022

Presentation ACC 2022

The Effects Of A Hypotension-avoidance Strategy Versus A Hypertension-avoidance Strategy In Patients Undergoing Noncardiac Surgery

Presenter: Maura Marcucci

April 04, 2022

Presentation ACC 2022

Long Term Efficacy and Safety of Renal Denervation on Blood Pressure in Patients on Antihypertension Medications: 3-Year Outcomes from the SPYRAL HTN-ON MED Trial

Presenter: Felix Mahfoud

April 04, 2022

Presentation THT 2022

CON - Patients with Group 2 Pulmonary Hypertension are not candidates for interatrial shunts!

Presenter: Liviu Klein

February 01, 2022

Presentation THT 2022

PRO - Patients with Group 2 Pulmonary Hypertension are not candidates for interatrial shunts!

Presenter: Roham Zamanian

February 01, 2022

Presentation TCT 2021

Outcomes of Pulmonary Artery Denervation for Treatment of PAH

Presenter: Gregg Stone

November 06, 2021

Presentation TCT 2021

Update On The Latest Clinical Evidence

Presenter: Ajay Kirtane

November 06, 2021

Presentation TCT 2021

Get To Know Ultrasound RDN (uRDN)

Presenter: Chandan Devireddy

November 06, 2021

Presentation TCT 2021

Establishing Consensus: US Guidance Updates

Presenter: Eric Secemsky

November 06, 2021

Presentation TCT 2021

Leading with Evidence: Latest Data on Renal Denervation

Presenter: NULL

November 06, 2021

Presentation TCT 2021

Cardiac Neuromodulation Therapy Effect on Systolic Blood Pressure and Pulse Pressure in Patients with Isolated Systolic Hypertension In A Randomized Double-Blind Study Together With Long Term Follow Up Results (Backbeat Medical)

Presenter: Daniel Burkhoff

November 05, 2021

Presentation TCT 2021

Latest Evidence in the SPYRAL-HTN Clinical Program

Presenter: NULL

November 05, 2021

Presentation TCT 2021

TCT 105: Impact of pulmonary hypertension differentiation on the outcome of patients undergoing MitraClip® therapy

Presenter: Tobias Schmidt

November 05, 2021

Presentation TCT 2021

Adequacy of Blood Pressure Control in High-Risk Hypertensive Patients: The DEGREE Study

Presenter: Victor Zeijen

November 04, 2021

Presentation TCT 2021

Cardiac Neuromodulation Therapy reduces Systolic Blood Pressure and Pulse Pressure in Patients With Isolated Systolic Hypertension in a Randomized Double-Blind Study

Presenter: Daniel Burkhoff

November 04, 2021

Presentation TCT 2021

Best Practices for the Future Implementation of Interventional Therapies for Hypertension

Presenter: Michael Bloch

November 04, 2021

Presentation TCT 2021

Debate: My Patient has a Blood Pressure of 150/90 Despite 2 Maximally Dosed Medications – Time for a Third Medication!

Presenter: Herbert D. Aronow

November 04, 2021

Advertisement

Blood pressure and MACE reductions after renal denervation: 3-year GSR results

Patient-Level Pooled Analysis of Ultrasound RDN in RADIANCE-HTN SOLO and TRIO

Current Status and Future of Renal Denervation for Hypertension

Anesthesia Update: Dealing with High-Risk Pulmonary Hypertension Patients

The Effects Of A Hypotension-avoidance Strategy Versus A Hypertension-avoidance Strategy In Patients Undergoing Noncardiac Surgery

Long Term Efficacy and Safety of Renal Denervation on Blood Pressure in Patients on Antihypertension Medications: 3-Year Outcomes from the SPYRAL HTN-ON MED Trial

CON - Patients with Group 2 Pulmonary Hypertension are not candidates for interatrial shunts!

PRO - Patients with Group 2 Pulmonary Hypertension are not candidates for interatrial shunts!

Outcomes of Pulmonary Artery Denervation for Treatment of PAH

Update On The Latest Clinical Evidence

Get To Know Ultrasound RDN (uRDN)

Establishing Consensus: US Guidance Updates

Leading with Evidence: Latest Data on Renal Denervation

Cardiac Neuromodulation Therapy Effect on Systolic Blood Pressure and Pulse Pressure in Patients with Isolated Systolic Hypertension In A Randomized Double-Blind Study Together With Long Term Follow Up Results (Backbeat Medical)

Latest Evidence in the SPYRAL-HTN Clinical Program

TCT 105: Impact of pulmonary hypertension differentiation on the outcome of patients undergoing MitraClip® therapy

Adequacy of Blood Pressure Control in High-Risk Hypertensive Patients: The DEGREE Study

Cardiac Neuromodulation Therapy reduces Systolic Blood Pressure and Pulse Pressure in Patients With Isolated Systolic Hypertension in a Randomized Double-Blind Study

Best Practices for the Future Implementation of Interventional Therapies for Hypertension

Debate: My Patient has a Blood Pressure of 150/90 Despite 2 Maximally Dosed Medications – Time for a Third Medication!

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content